Oncolytics Biotech

Oncolytics Biotech P/FCF

The P/FCF (Price-to-Free-Cash-Flow Ratio) of Oncolytics Biotech (ONCY) as of Oct 27, 2026 is -3.26. In the previous year, P/FCF (Price-to-Free-Cash-Flow Ratio) was -4.67 — a change of -30.32% (higher).

P/FCF

-3.26

YoY

-30.32%

Last updated:

P/FCF (Price-to-Free-Cash-Flow Ratio) of Oncolytics Biotech is 2025 -3.26 . P/FCF (Price-to-Free-Cash-Flow Ratio) of Oncolytics Biotech was 2024 -4.67 . It decreases by -30.32% higher compared to the previous year.

The Oncolytics Biotech P/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

P/FCF
Date
P/FCF
Jan 1, 2018
-10.57 USD
Jan 1, 2019
-6.38 USD
Jan 1, 2020
-5.75 USD
Jan 1, 2021
-5.60 USD
Jan 1, 2022
-5.43 USD
Jan 1, 2023
-4.47 USD
Jan 1, 2024
-4.67 USD
Jan 1, 2025
-3.26 USD
The Oncolytics Biotech P/FCF history
YEARP/FCFYoY
-3.26-30.32%
-4.67+4.60%
-4.47-17.73%
-5.43-2.95%
-5.60-2.74%
-5.75-9.87%
-6.38-39.61%
-10.57+24.69%
-8.48-16.64%
-10.17+21.13%
-8.40+30.95%
-6.41—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Oncolytics Biotech Stock analysis

What does Oncolytics Biotech do? Oncolytics Biotech Inc. develops pelareorep, an intravenously delivered immunotherapeutic agent targeting gastrointestinal tumors, metastatic colorectal cancer, anal cancer, and metastatic pancreatic cancer. The company generates revenue through research and development agreements, including a supply agreement with Roche Holding AG for atezolizumab, which is used in its sponsored studies. Oncolytics focuses on clinical-stage oncology treatments, leveraging partnerships to advance its pipeline without commercializing products yet. Roche Holding AG supplies atezolizumab under an agreement with Oncolytics, enabling the company to conduct studies on pelareorep in combination with immune checkpoint inhibitors. This collaboration supports Oncolytics' research efforts in oncology, particularly for GI tumor treatments and metastatic cancers. The company remains in the clinical development phase, with no current commercial products. Oncolytics Biotech Inc. operates as a clinical-stage biopharmaceutical company, concentrating on immunotherapeutic agents for specific cancer types. Its primary revenue stream comes from research partnerships, such as the Roche collaboration, rather than product sales. The company does not yet have commercialized treatments, relying instead on sponsored studies and development agreements to fund its operations. Oncolytics Biotech is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Oncolytics Biotech stock

P/FCF (Price-to-Free-Cash-Flow Ratio) of Oncolytics Biotech is -3.26 in 2025.

P/FCF (Price-to-Free-Cash-Flow Ratio) of Oncolytics Biotech changed from -4.67 to -3.26, representing a -30.32% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of P/FCF (Price-to-Free-Cash-Flow Ratio) Oncolytics Biotech since 2006 – with annual values, charts, and detailed analysis.

The Price-to-Free-Cash-Flow ratio measures how much investors pay for each unit of free cash flow. A lower ratio may indicate better value.

P/FCF = Market Capitalization / Free Cash Flow

To evaluate P/FCF (Price-to-Free-Cash-Flow Ratio)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for P/FCF (Price-to-Free-Cash-Flow Ratio).

A 'good' varies by industry and company stage. On Eulerpool, you can compare P/FCF (Price-to-Free-Cash-Flow Ratio)'s Oncolytics Biotech with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Valuation — Oncolytics Biotech

P/EP/SEV/EBITP/BP/CFP/FCFPEGEV/RevenueEV/EBITDAEV/FCFEarnings YieldFCF YieldMarket capitalizationEnterprise ValueForward P/EP/TBVShareholder YieldBuyback YieldDiv.-Adj. PEGEV/OCF

All Key Metrics — Oncolytics Biotech